Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Original Chronic Lymphocytic Leukemia International Prognostic Index

Five-factor additive prognostic index for CLL using TP53, IGHV, beta-2 microglobulin, clinical stage, and age.

Evidence-based context for fast calculator use

Purpose:
Assign the original CLL-IPI prognostic group from a complete baseline assessment.
Population:
Patients with chronic lymphocytic leukemia represented in the original international CLL-IPI dataset.
Factors:
del(17p) and/or TP53 mutation, Unmutated IGHV, Beta-2 microglobulin >3.5 mg/L, Binet B/C or Rai I-IV, Age >65 years
Reference:
International CLL-IPI Working Group. Lancet Oncol. 2016;17(6):779-790.
HomeCLL-IPI
Pin your most used calculators here by clicking the star in the dropdown.

CLL-IPI

Clinical Context & Background

The original Chronic Lymphocytic Leukemia International Prognostic Index (CLL-IPI) is a five-factor additive model. It assigns 4 points for del(17p) and/or TP53 mutation, 2 for unmutated IGHV, 2 for beta-2 microglobulin >3.5 mg/L, 1 for Binet B/C or Rai I-IV, and 1 for age >65 years.
Scores 0-1, 2-3, 4-6, and 7-10 define low, intermediate, high, and very high risk. The displayed 5-year overall survival values are historical observations from the original training cohort, not individualized current-era predictions. CLL-IPI is prognostic and does not determine when treatment should begin; treatment initiation follows iwCLL active-disease criteria.
Primary Source EvidenceInternational CLL-IPI Working Group. Lancet Oncol. 2016;17(6):779-790. doi:10.1016/S1470-2045(16)30029-8.
Formula Logic
TP53 disruption x 4 + unmutated IGHV x 2 + beta-2 microglobulin >3.5 mg/L x 2 + Binet B/C or Rai I-IV x 1 + age >65 years x 1.

Reference Data

Risk GroupScoreHistorical 5-year overall survival (original training cohort)
Low Risk0 - 193.2%
Intermediate Risk2 - 379.3%
High Risk4 - 663.3%
Very High Risk7 - 1023.3%

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use for prognostic stratification after CLL has been diagnosed and all five factors are known.
  • Enter TP53 disruption when del(17p), TP53 mutation, or both are present; use the exact >3.5 mg/L beta-2 microglobulin and >65-year age thresholds.

How To Interpret

  • Map the exact 0-10 total to low, intermediate, high, or very high risk.
  • Treat 93.2%, 79.3%, 63.3%, and 23.3% as historical 5-year overall survival observations from the original training cohort, not individualized current-era predictions.

What To Do Next

  • Document all five inputs, the total, risk group, assessment date, and disease context so the result can be reproduced.
  • Assess treatment initiation separately using iwCLL active-disease criteria and current CLL guidance; do not start therapy from CLL-IPI alone.

Limitations

  • The original outcome estimates predate widespread use of current targeted therapies and may not represent contemporary outcomes.
  • The score is prognostic; it does not replace individualized assessment, current treatment-selection guidance, or clinical judgment.

Validated Population

The original international CLL-IPI training and validation cohorts; displayed outcomes are explicitly historical training-cohort observations.

Interpret the group as historical prognosis

A score of 4 maps to high risk and the original training-cohort 5-year overall survival observation of 63.3%; it is not a current patient-specific survival prediction.

Hematology calculatorsReview related disease-specific prognostic tools.

Calculation verification history

Verified

  1. : Production browser revalidation

    • Three source-backed CLL-IPI cases passed through visible production controls at scores 0, 4, and 10.
    • The former radio-value form-boundary failure and invalid-result gauge were absent; no unexpected N/A, literal undefined value, stale control, or browser-console error was observed.
    Download latest production check (Excel)

    Case-level evidence is retained in validation/browser-revalidation/cll-ipi-chronic-lymphocytic-leukemia-index-2026-08-03.json.

  2. : Local browser remediation verified; production retest pending

    • Updated the CLL-IPI public form adapter to accept the exact numeric 0/1 values emitted by its radio controls while preserving the strict calculation engine.
    • Ten local visible-browser cases passed across scores 0, 1, 2, 3, 4, 6, 7, and 10, all four risk groups, missing-field feedback, and reset/repeat behavior.
    • The original failed production-browser finding remains open until deployment and a fresh public run.

    Local diagnostic evidence is retained in validation/browser-production/cll-ipi-chronic-lymphocytic-leukemia-index.local-remediation.json.

  3. : Production browser validation

    • Ten source-backed cases were exercised on the public production route through visible browser controls; 1/10 case records passed their expected-versus-observed assertions across 11 visible submissions.
    • Overall browser status: failed-calculation-ui-and-console. critical: Every fully completed valid profile rendered N/A / Invalid Input with `Provide exactly one valid response for each of the 5 CLL-IPI factors.` A supplemental maximum-profile reproduction showed all five radio groups checked immediately before Calculate. | medium: The invalid result card also displayed a generic Low Risk / Intermediate / High Risk gauge despite the unavailable result and the source model's four groups. | medium: Production emitted minified React error #418 during route loads/reloads used by this run.
    • Case-level inputs, expected and observed results, reset/repeat behavior, failure reproductions, and console evidence are retained in the production-browser evidence record.

    Case-level production evidence is retained in validation/browser-production/cll-ipi-chronic-lymphocytic-leukemia-index.json.

  4. : Full validation test

    • Verified all 32 valid combinations, every factor weight, score/group boundaries 1/2, 3/4, and 6/7, maximum 10, historical outcome mapping, additive trace, strict invalid-input rejection, no-default behavior, immutability, and exact UI serialization.

  5. : Correction history

    • Removed favorable defaults and permissive point summation, required all five exact binary inputs, labeled survival values as historical original-training-cohort observations, and removed the unsupported implication that CLL-IPI determines treatment timing.

Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.

Found a possible issue? Report it to improve this calculator

Share This Calculator

Share:

Related Tools

NCCN-IPI (Lymphoma)Original Continuous MIPI (Mantle Cell Lymphoma)IPS (Hodgkin Lymphoma)

Frequently Asked Questions

What counts as TP53 disruption?

The original CLL-IPI TP53 factor is present when del(17p), a TP53 mutation, or both are detected.

Are the displayed 5-year survival percentages current individualized predictions?

No. They are historical observations from the original CLL-IPI training cohort and should not be interpreted as patient-specific current-era predictions.

Does CLL-IPI determine when treatment starts?

No. Treatment initiation is assessed separately using iwCLL active-disease criteria and current clinical guidance.

Evidence-based oncology decision support. Verify with clinical guidelines.